All In Biotech

Drug Trial Radar · NCT01677182

Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects

Last checked: Nov 20, 2026Latest source record: Mar 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 535 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

535

Actual

Start

Aug 2012

Primary completion

Aug 2014

Study completion Sep 2014

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Aug 31, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of ramelteon for treatment of acute depressive episodes associated with Bipolar 1 Disorder.

Conditions

  • Bipolar Disorder

Interventions

  • RamelteonDrug

    Ramelteon tablets for sublingual administration

  • PlaceboDrug

    Ramelteon placebo-matching tablets for sublingual administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6Time frame: Baseline and Week 6

Locations

104 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Anaheim, California

  • Site not named

    Glendale, California

  • Site not named

    Imperial, California

  • Site not named

    Los Angeles, California

  • Site not named

    Oakland, California

  • Site not named

    Oceanside, California

  • Site not named

    Pico Rivera, California

  • Site not named

    San Diego, California

  • Site not named

    Stanford, California

  • Site not named

    Hartford, Connecticut

  • Site not named

    Coral Springs, Florida

  • Site not named

    Deerfield Beach, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Maitland, Florida

  • Site not named

    Oakland Park, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Joliet, Illinois

  • Site not named

    Naperville, Illinois

  • Site not named

    Oak Brook, Illinois

  • Site not named

    Lafayette, Indiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    St Louis, Missouri

  • Site not named

    Buffalo, New York

  • Site not named

    New York, New York

  • Site not named

    Staten Island, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Avon Lake, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Garfield Heights, Ohio

  • Site not named

    Mason, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Memphis, Tennessee

  • Site not named

    San Antonio, Texas

  • Site not named

    Bothell, Washington

  • Site not named

    Spokane, Washington

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.